Approximately 90% of EGFR mutations in non‐small cell lung cancer (NSCLC) are “classic mutations” (19del, L858R, etc.)that are sensitive to treatment with EGFR tyrosine kinase inhibitors (TKIs).3, 4. This evidence concerns the gene EGFR and non-small cell lung carcinoma.